Tocci Noah X, Wehrle Chase J, Sun Keyue, Jiao Chunbao, Hong Hanna, Gross Abby, Allkushi Erlind, Uysal Melis, Linganna Maureen Whitsett, Stackhouse Katheryn, Hashimoto Koji, Schlegel Andrea, Walsh R Matthew, Miller Charles, Kwon David C H, Aucejo Federico
Department of Hepato-pancreato-biliary & Liver Transplant Surgery, Digestive Diseases and Surgery Institute, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
Lerner Research Institute, Inflammation & Immunity, Cleveland Clinic Foundation, Cleveland, Ohio, USA.
J Surg Oncol. 2025 Apr;131(5):879-887. doi: 10.1002/jso.27825. Epub 2024 Aug 19.
Primary liver malignancies are a serious and challenging global health concern. The most common primary tumors are hepatocellular carcinoma and cholangiocarcinoma. These diseases portend poor prognosis when presenting with progressive, extensive disease. There is a critical need for improved diagnosis, therapeutic intervention, and monitoring surveillance in liver-related malignancies. Liquid biopsy using ctDNA provides an opportunity for growth within these domains for liver-related malignancy. However, ctDNA is relatively understudied in this field compared with other solid tumor types, possibly due to the complex nature of the pathology. In this review, we aim to discuss ctDNA, the current literature, and future directions of this technology within primary liver malignancies.
原发性肝脏恶性肿瘤是一个严重且具有挑战性的全球健康问题。最常见的原发性肿瘤是肝细胞癌和胆管癌。当这些疾病呈现为进行性、广泛性病变时，预后不佳。在肝脏相关恶性肿瘤中，迫切需要改进诊断、治疗干预和监测。使用循环肿瘤DNA（ctDNA）进行液体活检为肝脏相关恶性肿瘤在这些领域的发展提供了契机。然而，与其他实体瘤类型相比，ctDNA在该领域的研究相对较少，这可能是由于病理学的复杂性所致。在本综述中，我们旨在讨论ctDNA、当前的文献以及该技术在原发性肝脏恶性肿瘤中的未来发展方向。
